Nearly 2 in 5 Study Participants Had Significant Hair Regrowth. Results from two phase 3 trials on baricitinib were published in The New England Journal of Medicine on May 5, 2022. A total of ...

Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol . 2024;38(4):687-694. doi:10.1111/jdv ...

The FDA has approved deuruxolitinib, an oral medication developed by Sun Pharma, as the first-line treatment for adults with moderate to severe alopecia areata.

Alopecia areata (AA) is an autoimmune condition that’s caused by the immune system’s attack on hair follicles, affecting new hair growth. “When this happens, the hairs gradually become ...

Frequently, patients with alopecia areata have hairs with the shape of an exclamation mark on the border of the bald patch. Hairs become weak and fall out easily.

Alopecia areata is an autoimmune disorder that usually results in unpredictable, patchy hair loss. Approximately 7 million people in the U.S. have alopecia areata, and it can affect anyone of any ...

Alopecia areata (AA) is a nonscarring hair loss that most commonly occurs over the scalp but can ... and the presence of “exclamation point” hairs.1 If the type of alopecia cannot be ...

Alopecia areata (AA) is a nonscarring alopecia that appears to involve T-cell-mediated autoimmune pathology. Eighty percent of patients present with a single coin-shaped area of hair loss, usually ...

On pathology, distorted follicular anatomy is found, once again supporting the need for a dermatopathologist to read any scalp/hair biopsy. Treatment is a combination of patient realization of the ...